Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.55 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.43 |
| ▸ | CEL | P19835 | 2/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | ADH1B | P00325 | 1/20 | 0.36 |
| ▸ | ADH1C | P00326 | 1/20 | 0.36 |
| ▸ | ADH1A | P07327 | 1/20 | 0.36 |
| ▸ | ADH4 | P08319 | 1/20 | 0.36 |
| ▸ | ADH7 | P40394 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.35 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8080519 | 0.97 | CYP1A2 (0.65) | CYP1A2SIGMAR1SLC18A3CELEPHX1 | |
| SCHEMBL454467 | 0.93 | CYP1A2 (0.68) | CYP1A2SIGMAR1SLC18A3CELEPHX1 | |
| SCHEMBL4969658 | 0.93 | CYP1A2 (0.68) | CYP1A2SIGMAR1SLC18A3CELEPHX1 | |
| SCHEMBL793959 | 0.93 | CYP1A2 (0.52) | CYP1A2SIGMAR1SLC18A3CELEPHX1 | |
| SCHEMBL10579794 | 0.93 | CYP1A2 (0.68) | CYP1A2SIGMAR1SLC18A3CELEPHX1 | |
| SCHEMBL10643742 | 0.93 | SIGMAR1 (0.62) | CYP1A2SIGMAR1SLC18A3CELEPHX1 | |
| SCHEMBL11503388 | 0.93 | CYP1A2 (0.68) | CYP1A2SIGMAR1SLC18A3CELEPHX1 | |
| SCHEMBL324846 | 0.89 | SIGMAR1 (0.65) | CYP1A2SIGMAR1SLC18A3CELEPHX1 | |
| SCHEMBL11481678 | 0.87 | SIGMAR1 (0.71) | CYP1A2SIGMAR1EPHX1KDM5AKDM4C | |
| SCHEMBL5614191 | 0.86 | SIGMAR1 (0.70) | CYP1A2SIGMAR1CELEPHX1KDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970146-B1 | ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR | ABBVIE DEUTSCHLAND (DE) | 2017-11-01 | — | — | EP | disclosed |
| US-9388141-B2 | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor | ABBVIE INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-9388148-B2 | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor | ABBVIE INC. (US) | 2016-07-12 | — | — | US | disclosed |
| EP-2970146-A1 | ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-20 | — | — | EP | disclosed |
| US-20140303176-A1 | ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-10-09 | — | — | US | disclosed |
| WO-2014140246-A1 | ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275104-A1 | ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | US | disclosed |
| US-7893269-B2 | amidation of 3-(benzyloxy)-1-cyclopropyl-6-methyl-4-oxo-1,4-dihydropyridine-2-carboxylic acid via the 2-acid chloride and then reaction with an amine; hydrolysis or catalytic hydrogenation to deprotect 3-hydroxy group; high yields for industrial application; the 3-(benzyloxy)-2-carboxamide intermediate | APOTEX INC (CA) | 2011-02-22 | — | — | US | disclosed |
| US-20080096886-A1 | Process For The Manufacture Of 3-Hydroxy-N-Alkyl-1-Cycloalkyl-6-Alkyl-4-Oxo-1,4-Dihydropyridine-2-Carboxamide And Its Related Analogues | APOTEX INC. (CA) | 2008-04-24 | — | — | US | disclosed |
| US-20050032793-A1 | 2-amino-benzoxazinones for the treatment of viral infections | G.D. SEARLE & CO. (US) | 2005-02-10 | — | — | US | disclosed |
| US-6683077-B2 | 4H-3,1-BENZOXAZIN-4-ONE COMPOUNDS OF GIVEN FORMULA; HERPES INFECTIONS; ASSEMBLIN PROTEASE INHIBITORS | G.D. SEARLE & CO. | 2004-01-27 | — | — | US | disclosed |
| US-20030022895-A1 | 2-Amino-benzoxazinones for the treatment of viral infections | G.D. SEARLE & CO. | 2003-01-30 | — | — | US | disclosed |
| US-6380189-B1 | FOR TREATING HERPES-RELATED DISORDERS | G.D. SEARLE & CO. | 2002-04-30 | — | — | US | disclosed |
| EP-1122245-A2 | 2-Amino-benzoxazinones for the treatment of viral infections | G.D. Searle & Co. (US) | 2001-08-08 | — | — | EP | disclosed |
| US-6087360-A | TREATING PATIENTS WITH ENDOTHELIN RELATED DISORDERS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2000-07-11 | — | — | US | disclosed |
| WO-1996037485-A1 | 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS | G.D. SEARLE & CO. (US) | 1996-11-28 | — | — | WO | disclosed |
| US-4775695-A | TREATMENT OF BRAIN INJURIES AND EDEMA | MERCK & CO., INC. (US) | 1988-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022895-A1 | 2-Amino-benzoxazinones for the treatment of viral infections | IFNAR1, IL4I1, HAX1 | CYP1A2 965/4885SIGMAR1 384/4885SLC18A3 4059/4885 |
| US-20050032793-A1 | 2-amino-benzoxazinones for the treatment of viral infections | IFNAR1, IL4I1, ACE2 | CYP1A2 778/4885SIGMAR1 533/4885SLC18A3 3607/4885 |
| US-20140275104-A1 | ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR | DRD3, DRD2, ADCY3 | CYP1A2 587/4885SIGMAR1 191/4885SLC18A3 267/4885 |
| US-20140303176-A1 | ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR | DRD3, DRD2, ADCY3 | CYP1A2 587/4885SIGMAR1 191/4885SLC18A3 267/4885 |
| US-20080096886-A1 | Process For The Manufacture Of 3-Hydroxy-N-Alkyl-1-Cycloalkyl-6-Alkyl-4-Oxo-1,4-Dihydropyridine-2-Carboxamide And Its Related Analogues | ADH1C, ADH1A, ADH5 | CYP1A2 89/4885SIGMAR1 44/4885SLC18A3 3751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.